Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, the premier U.S. sexual wellness industry event. The award will be presented today, August 5, 2025, during the conference held in Nashville, Tennessee.

The STIMULATE Conference is North America's only trade show and leadership summit focused exclusively on sexual wellness, innovation, and empowerment. This year, Saundra Pelletier will be recognized alongside an elite group of female founders who are redefining what it means to lead in spaces historically overlooked — especially when it comes to reproductive health, autonomy, and the language we use to discuss them.

This honor is especially meaningful as it falls during Say Vagina Month— a bold public initiative launched by Evofem to end the shame and censorship surrounding vaginal health and advocate for medically accurate, empowering language in healthcare and social discourse.

"When we talk about birth control, the message is almost always fear-based," said Saundra Pelletier. "But let's be honest: if we're using birth control, it's because of sex. So, let's talk about sex. Let's talk about satisfaction. Let's talk about pleasure. Because women deserve more than prevention — they deserve agency, honesty, and joy in the conversation. That's what this award means to me."

Evofem engages healthcare providers on the importance of addressing sexual satisfaction as part of their contraceptive counseling, leveraging compelling data published in the Journal of Sexual Medicine.  The data demonstrate that nearly 90% of women using Evofem's hormone-free contraceptive, PHEXXI® (lactic acid, citric acid, and potassium bitartrate), improved or maintained their level of sexual satisfaction in the Phase 3 AMPOWER trial.

As a company led by women and committed to empowering women through science, advocacy, and access, Evofem views this recognition as not just an award — but a call to keep pushing forward.

About Evofem Biosciences

Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

• PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.  
• SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. 

Evofem's commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the U.S. The Company is entering global markets through strategic partnerships, including a license agreement for the Middle East and North Africa under which PHEXXI and SOLOSEC are expected to launch in the UAE in 2026.

As previously announced, Evofem entered into a definitive agreement to be acquired by Aditxt, Inc. (Nasdaq: ADTX). Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to add a dedicated to women's health program to its social innovation platform accelerating promising health innovations. The companies are working toward a targeted close in the second half of 2025.

PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. The closing of the transaction with Evofem, Aditxt and Adifem, Inc., under the A&R Merger Agreement, as amended, is subject to several conditions including, but not limited to, 1) approval of the transaction by a majority of the combined voting power of Evofem's E-1 and Common Stock, voting together as a single class, at a meeting where quorum is present, and 2) Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15 million required to satisfy Evofem's senior secured noteholder. Should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.  You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contact
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775

SOURCE Evofem Biosciences, Inc.